A=375 Belvarafenib 50mg QD Cobi 20mg QOD		A-375 Belvarafenib 100mg BID Cobi 20mg QOD	A-375 Belvarafenib 200mg Cobi 20mg QOD		A–375 Belvarafenib 400mg BID Cobi 20mg QOD	A-375 Belvarafenib 50mg QD Cobi 20mg QD	A-375 Belvarafenib 100mg BID Cobi 20mg QD		A-375 Belvarafenib 200mg QD Cobi 20mg QD	A–375 Belvarafenib 40 Cobi 20mo	mg BID QD	A–375 Belvarafenib 50mg QD Cobi 40mg QD		A–375 Belvarafenib 100mg BID Cobi 40mg QD		A–375 Belvarafenib 200mg QD Cobi 40mg QD		A-375 Belvarafenib 400mg BID Cobi 40mg QD		A-375 Belvarafenib 50mg QD Cobi 60mg QD		A–375 Belvarafenib 100mg BID Cobi 60mg QD		A–375 Belvarafenib 200mg QD Cobi 60mg QD		A–375 Belvarafenib 400mg BID Cobi 60mg QD	
	Relative Viability	RelativeVial 1.00 0.75 0.50 0.25 0.00	bility WEK! Copimetinib uM -3	RelativeViability 1.00 0.75 0.50 0.25 0.00 -3		Relative Viability 1.00 WE of the second o	RelativeViability 1.00 0.75 0.50 0.25 0.00 -3	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3 -		Relative Viability	RelativeViability 1.00 0.75 0.50 0.25 0.00	-2-	Relative Viability		Relative Viability		RelativeViability		Relative Viability 1.00		Relative Viability		RelativeViability		Relative Viability		RelativeViat - 1.00 - 0.75 - 0.50 - 0.25 0.00
panRAFi_Belvarafenib uM A-375 Belvarafenib 50mg QD Cobi 20mg QOD		panRAFi_Belvarafenib uM A-375 Belvarafenib 100mg BID Cobi 20mg QOD	-4 -3 panRAFi_Belvarafenib A-375 Belvarafenib 200mg Cobi 20mg QOI		-4 -3 -2 panRAFi_Belvarafenib uM A-375 Belvarafenib 400mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM A-375 Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 panRAFi_Belvarafenib uM A-375 Belvarafenib 100mg BID Cobi 20mg QD		panRAFi_Belvarafenib uM A-375 Belvarafenib 200mg QD Cobi 20mg QD	-4 -3 panRAFi_Belvar A-3 Belvarafenib Cobi 20r	enib uM Jomg BID J QD	-4 -3 -2 panRAFi_Belvarafenib uM A-375 Belvarafenib 50mg QD Cobi 40mg QD		panRAFi_Belvarafenib uM A-375 Belvarafenib 100mg BID Cobi 40mg QD		-4 -3 -2 panRAFi_Belvarafenib uM A-375 Belvarafenib 200mg QD Cobi 40mg QD		-4 -3 -2 panRAFi_Belvarafenib uM A-375 Belvarafenib 400mg BID Cobi 40mg QD	-4 -4	panRAFi_Belvarafenib uM A-375 Belvarafenib 50mg QD Cobi 60mg QD		panRAFi_Belvarafenib uM A-375 Belvarafenib 100mg BID Cobi 60mg QD		-4 -3 -2 panRAFi_Belvarafenib uM A-375 Belvarafenib 200mg QD Cobi 60mg QD		panRAFi_Belvarafenib uM A-375 Belvarafenib 400mg BID Cobi 60mg QD	
	HSA Excess 0.50 0.25 0.00 0.00 0.25 -0.25 -0.50 -3	HSA Ext	Cess (0.50) Wn -2 (0.25) (1.50) Wn William (0.00) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (1.50) (HSA Excess 0.50 Wn -2 0.25 0.00 -0.25 -0.50 -0.50 -3		HSA Excess 0.50 0.00 0.00 0.25 0.50 0.00 0.25 0.50 0.00 0.25 0.00 0.25 0.00 0.25 0.00 0.00	HSA Excess 0.50 0.00 0.00 0.00 0.25 0.00 0.50 -0.25 -0.50 -3	HSA Excess 0.50 0.00 0.00 0.00 -0.25 -0.50 -0.50 -0.50 -0.50 -0.50 -0.50 -0.50 -0.50 -0.50 -0.50		HSA Excess 0.50 Do 00 0.00 0.00 0.00 -0.25 -0.50 -3	HSA Excess 0.50 0.25 0.00 -0.25 -0.50	-2-	HSA Excess 0.50 0.25 0.00 0.00 0.25 -0.50 -0.50 -3 =		HSA Excess 0.50 0.25 0.00 0.00 0.25 -0.25 -0.50 -3		HSA Excess 0.50 0.25 0.00 0.00 0.25 -0.25 -0.50 -3		HSA Excess 0.50 0.25 0.00 0.00 0.00 -0.25 -0.50 -0.50 -0.50 -0.50		HSA Excess 0.50 0.25 0.00 0.00 0.25 -0.25 -0.50 -3		HSA Excess 0.50 0.25 0.00 0.00 0.25 -0.25 -0.50 -3		HSA Excess 0.50 0.25 0.00 -0.25 -0.50 -3		HSA Exc
Cobi 20mg QD		Cobi 20mg QOD	Cobi 20mg QOI	טו	Cobi 20mg QOD	Cobi 20mg QD	Cobi 20mg QD	I	Cobi 20mg QD	Cobi 20r	I QD	Cobi 40mg QD		Cobi 40mg QD	1	Cobi 40mg QD		Cobi 40mg QD		Cobi 60mg QD		Cobi 60mg QD		Cobi 60mg QD		Cobi 60mg QD	
	Bliss Excess 0.50 0.25 0.00 0.00 0.00 -0.25 -0.50 -3	Bliss Exc	Cess 2.50 Win -2 - 2.25 Wing Windows W	Bliss Excess 0.50 0.00 0.00 -0.25 -0.25 -0.50 -0.50 -3		Bliss Excess 0.50 0.00 0.00 -0.25 -0.25 -0.50 -0.50 -3	Bliss Excess 0.50 Mn quijaming on the property of the proper	Bliss Excess 0.50 Wn -2 - 0.25 0.00 -0.25 WBW -3 -		Bliss Excess 0.50 Wn -2 - 0.25 0.00 OOD -0.25 -0.50 -3 -	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50	-2-	Bliss Excess 0.50 0.25 0.00 0.00 -0.25 -0.50 -0.50 -3 =		Bliss Excess 0.50 Wn qiuibwiiqoO 0.00 -0.25 -0.25 -0.50 -0.50 -3		Bliss Excess 0.50 Wn -2 - 0.25 0.00 0.00 -0.25 WEXE 0.50 -0.50 -3 -		Bliss Excess 0.50 In quitibuting the properties of the propertie		Bliss Excess 0.50 In question in the property of the propert		Bliss Excess 0.50 0.25 0.00 0.00 -0.25 WE WITH THE PROPERTY OF THE PROPE		Bliss Excess 0.50 Wn -2 - 0.25 0.00 -0.25 -0.50 -0.50 -3 -		Bliss Exc
panRAFi_Belvarafenib uM IPC-298 Belvarafenib 50mg QD Cobi 20mg QOD		panRAFi_Belvarafenib uM IPC-298 Belvarafenib 100mg BID Cobi 20mg QOD	-4 - 3 panRAFi_Belvarafenil IPC-298 Belvarafenib 200mg Cobi 20mg QOD		-4 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 400mg BID Cobi 20mg QOD	-4 -4 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 50mg QD Cobi 20mg QD	-4 -4 -3 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 100mg BID Cobi 20mg QD	-4 	-4 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 200mg QD Cobi 20mg QD	-4 -3 panRAFi_Belv IPC-29 Belvarafenib 40 Cobi 20me	mg BID	-4 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 50mg QD Cobi 40mg QD		-4 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 100mg BID Cobi 40mg QD		-4 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 200mg QD Cobi 40mg QD		-4 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 400mg BID Cobi 40mg QD	-4 	panRAFi_Belvarafenib uM IPC-298 Belvarafenib 50mg QD Cobi 60mg QD		panRAFi_Belvarafenib uM IPC-298 Belvarafenib 100mg BID Cobi 60mg QD		-4 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 200mg QD Cobi 60mg QD		1 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 400mg BID Cobi 60mg QD	
	Relative Viability	RelativeVial 1.00 0.75 0.50 0.25 0.00	bility WEKi_Cobimetinib uM -3 -	RelativeViability 1.00 0.75 0.50 0.25 0.00 -3	Rel	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 50mg QD	Relative Viability 1.00 90 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3 -		Relative Viability 1.00 90.75 0.50 0.25 0.00 -3	Relative Viability 1.00 0.75 0.50 0.25 0.00	-1- -2- -3-	Relative Viability		Relative Viability - 1.00 Wn -2 0.75 Giuipe i goo O O O O O O O O O O O O O O O O O O		RelativeViability - 1.00		Relative Viability		Relative Viability		Relative Viability		Relative Viability 1.00 0.75 0.50 0.25 0.00 -3		RelativeVial 1.00 - 0.75 - 0.50 - 0.2t 0.0
-4 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 50mg QD Cobi 20mg QOD	-4 -4	-3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 100mg BID Cobi 20mg QOD	-4 -3 panRAFi_Belvarafenib IPC-298 Belvarafenib 200mg Cobi 20mg QOI		-4 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 400mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM IPC-298 Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 100mg BID Cobi 20mg QD	_4	panRAFi_Belvarafenib uM IPC-298 Belvarafenib 200mg QD Cobi 20mg QD	-4 -3 panRAFi_Belvar IPC-2 Belvarafenib Cobi 20r	enib uM 8 00mg BID J QD	panRAFi_Belvarafenib uM IPC-298 Belvarafenib 50mg QD Cobi 40mg QD		panRAFi_Belvarafenib uM IPC-298 Belvarafenib 100mg BID Cobi 40mg QD		-4 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 200mg QD Cobi 40mg QD		-4 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 400mg BID Cobi 40mg QD	-4 -4	panRAFi_Belvarafenib uM IPC-298 Belvarafenib 50mg QD Cobi 60mg QD		-3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 100mg BID Cobi 60mg QD		-4 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 200mg QD Cobi 60mg QD		-4 -3 -2 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 400mg BID Cobi 60mg QD	_
	HSA Excess 0.6	HSA EX	Cess 2.6 What -2 - 0.3 We will be seen to be	HSA Excess 0.6 0.3 0.0 0.0 -0.3 -0.6 -0.6 -3		HSA Excess 0.6 0.7 0.0 0.0 0.0 -0.6 -3	HSA Excess 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	HSA Excess 0.6 0.0 0.0 0.0 -0.3 -0.6 -3-		HSA Excess 0.6	HSA Excess 0.6 0.3 0.0 -0.3 -0.6	-1 - 1 - 2 2 3 3 4	HSA Excess 0.6		HSA Excess 0.6 0.7 0.0 0.0 -0.3 -0.6 -3		HSA Excess 0.6 Wp -2 - 0.3 integration of the control of the cont		HSA Excess 0.6 0.7 0.0 0.0 -0.3 -0.6 -0.6 -3		HSA Excess 0.6		HSA Excess 0.6		HSA Excess 0.6 0.7 0.0 0.0 0.0 0.0 -0.6 -3		HSA Exc
panRAFi_Belvarafenib uM IPC-298 Belvarafenib 50mg QD Cobi 20mg QOD	-4	panRAFi_Belvarafenib uM IPC-298 Belvarafenib 100mg BID Cobi 20mg QOD	-4 -3 panRAFi_Belvarafenil IPC-298 Belvarafenib 200mg Cobi 20mg QOI		panRAFi_Belvarafenib uM IPC-298 Belvarafenib 400mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM IPC-298 Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 panRAFi_Belvarafenib uM IPC-298 Belvarafenib 100mg BID Cobi 20mg QD	-2	panRAFi_Belvarafenib uM IPC-298 Belvarafenib 200mg QD Cobi 20mg QD	-4 -3 panRAFi_Belv IPC-2 Belvarafenib Cobi 20r	-2 afenib uM 8 0mg BID QD	panRAFi_Belvarafenib uM IPC-298 Belvarafenib 50mg QD Cobi 40mg QD	- 	panRAFi_Belvarafenib uM IPC-298 Belvarafenib 100mg BID Cobi 40mg QD		panRAFi_Belvarafenib uM IPC-298 Belvarafenib 200mg QD Cobi 40mg QD		panRAFi_Belvarafenib uM IPC-298 Belvarafenib 400mg BID Cobi 40mg QD	-4	panRAFi_Belvarafenib uM IPC-298 Belvarafenib 50mg QD Cobi 60mg QD	- 	panRAFi_Belvarafenib uM IPC-298 Belvarafenib 100mg BID Cobi 60mg QD		panRAFi_Belvarafenib uM IPC-298 Belvarafenib 200mg QD Cobi 60mg QD		panRAFi_Belvarafenib uM IPC-298 Belvarafenib 400mg BID Cobi 60mg QD	
-4 -3 -2	Bliss Excess 0.6 0.0 0.0 0.0 -0.3 -0.6 -3 -4 -4	Bliss Ext	Cess 1.6 What is a second of the control of the con	Bliss Excess 0.6 0.0 0.0 -0.3 -0.6 -3	-4 -3 -2 -2	Bliss Excess Occupant Occupant Description Descriptio	Bliss Excess 0.6 0.0 0.0 0.0 -0.3 -0.6 -3 -4 -4 -3	Bliss Excess 0.6 0.0 0.0 0.0 -0.3 -0.6 -0.6 -3-		Bliss Excess 0.6 0.0 -0.3 -0.6 -3 -4 -4 -3	Bliss Excess 0.6 0.3 0.0 -0.3 -0.6		Bliss Excess 0.6 0.3 0.0 -0.3 -0.6 -3 =		Bliss Excess 0.6 0.7 0.0 0.0 -0.3 -0.6 -3 -4	-3 -2 -2	Bliss Excess 0.6 0.0 0.0 0.0 -0.3 -0.6 -3	-4 -3 -2	Bliss Excess 0.6 0.0 0.0 -0.3 -0.6 -3 -4		Bliss Excess 0.6 0.0 0.0 -0.3 -0.6 -3		Bliss Excess 0.6 0.3 0.0 -0.3 -0.6 -3 -4		Bliss Excess 0.6 0.0 0.0 -0.3 -0.6 -3	-4 -3 -2	Bliss Exc